RxDoctor Payments Data

Ashwin Kumar

Medical · Claremont, NHNPI 1275931776

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $699 of the $956 with a category attached, or 73.1%. 10 manufacturers reported payments, led by Johnson & Johnson at 33.7% of the total.

$956in general payments, 2019–2025

Across 36 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$322
  • Sanofi-aventis U.S. LLC$157
  • Regeneron Healthcare Solutions, Inc.$100
  • Galderma Laboratories, L.p.$88
  • E.r. Squibb & Sons, L.L.C.$78
  • LEO Pharma Inc.$62
  • plus $150 from 4 others

What the payments were for

  • Food & beverage$69973%
  • Education$25727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$956 in reported general payments places this provider in the 80th percentile of 124 medical providers in New Hampshire.

See all medical providers in New Hampshire

Medicare billing

Part B allowed, 2024
$306,060
Medicare patients
1,093
Services billed
5,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab77$296,633
TremfyaGuselkumab22$296,316
Dupixent PenDupilumab67$261,943
Cosentyx Sensoready (2 Pens)Secukinumab26$209,851
OtezlaApremilast16$110,940
Clobetasol Propionate115$4,436
Doxycycline Hyclate59$2,443
Metronidazole44$2,032
Triamcinolone Acetonide135$1,668
Ketoconazole84$1,158
Alclometasone Dipropionate22$808
Halobetasol Propionate19$803
Clindamycin Phosphate30$687
Mometasone Furoate31$601
Minoxidil29$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$322$296,31622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 124 medical providers in New Hampshire.

Other medical in Claremont

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →